Search hospitals
>
New Jersey
>
Hackensack
Hackensack University Medical Center
Claim this profile
Hackensack, New Jersey 07601
Global Leader in Cancer
Global Leader in Lymphoma
Conducts research for Leukemia
Conducts research for Multiple Myeloma
Conducts research for Solid Tumors
982 reported clinical trials
52 medical researchers
Summary
Hackensack University Medical Center is a medical facility located in Hackensack, New Jersey. This center is recognized for care of Cancer, Lymphoma, Leukemia, Multiple Myeloma, Solid Tumors and other specialties. Hackensack University Medical Center is involved with conducting 982 clinical trials across 1,009 conditions. There are 52 research doctors associated with this hospital, such as Martin E Gutierrez, Katharine Offer, Burton E. Appel, and Derek Hanson, MD.
Area of expertise
Cancer
Hackensack University Medical Center has run 135 trials for Cancer. Some of their research focus areas include:
Lymphoma
Hackensack University Medical Center has run 94 trials for Lymphoma. Some of their research focus areas include:
Top PIs
Martin E Gutierrez
John Theurer Cancer Center at Hackensack University Medical Center
3 years of reported clinical research
Katharine Offer
Hackensack University Medical Center
8 years of reported clinical research
Burton E. Appel
Hackensack University Medical Center
6 years of reported clinical research
Derek Hanson, MD
Hackensack University Medical Center
3 years of reported clinical research
Clinical Trials running at Hackensack University Medical Center
Bladder Cancer
Breast Cancer
Brain Tumor
Prostate Cancer
Breast cancer
Wilms Tumor
Cancer
Kidney Cancer
Testicular cancer
Multiple Myeloma
Gemcitabine + BCG
for Bladder Cancer
This phase III trial compares the effect of adding gemcitabine to intravesical Bacillus Calmette Guerin (BCG) versus intravesical BCG alone in patients with non-muscle invasive bladder cancer that has come back after a period of improvement (recurrent). Gemcitabine is a chemotherapy drug that blocks the cells from making deoxyribonucleic acid (DNA) and may kill cancer cells. Intravesical BCG is a solution containing the live BCG bacteria that is placed in the bladder via a catheter (intravesical). When the solution comes into direct contact with the bladder wall, it stimulates the body's immune system which kills tumor cells. Giving gemcitabine with intravesical BCG may kill more tumor cells in patients with recurrent non-muscle invasive bladder cancer.
Recruiting
2 awards
Phase 3
10 criteria
Gemcitabine + Docetaxel vs BCG
for Bladder Cancer
This trial is testing whether a combination of two drugs, Gemcitabine and Docetaxel, given directly into the bladder, is effective for patients with high-grade non-muscle invasive bladder cancer who have not been treated with the standard therapy before. The goal is to see if this new treatment can prevent cancer from coming back or spreading. The study will also look at the quality of life, safety, and side effects of the new treatment. Gemcitabine and Docetaxel have shown promise as an alternative treatment, especially in cases where the standard therapy fails or is not tolerated.
Recruiting
2 awards
Phase 3
14 criteria
Blood Test and Immunotherapy
for Bladder Cancer
This phase II/III trial examines whether patients who have undergone surgical removal of bladder, kidney, ureter or urethra, but require an additional treatment called immunotherapy to help prevent their urinary tract (urothelial) cancer from coming back, can be identified by a blood test. Many types of tumors tend to lose cells or release different types of cellular products including their DNA which is referred to as circulating tumor DNA (ctDNA) into the bloodstream before changes can be seen on scans. Health care providers can measure the level of ctDNA in blood or other bodily fluids to determine which patients are at higher risk for disease progression or relapse. In this study, a blood test is used to measure ctDNA and see if there is still cancer somewhere in the body after surgery and if giving a treatment will help eliminate the cancer. Immunotherapy with monoclonal antibodies, such as nivolumab and relatlimab, can help the body's immune system to attack the cancer, and can interfere with the ability of tumor cells to grow and spread. This trial may help doctors determine if ctDNA measurement in blood can better identify patients that need additional treatment, if treatment with nivolumab prolongs patients' life and whether the additional immunotherapy treatment with relatlimab extends time without disease progression or prolongs life of urothelial cancer patients who have undergone surgical removal of their bladder, kidney, ureter or urethra.
Recruiting
1 award
Phase 2 & 3
10 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Hackensack University Medical Center?
Hackensack University Medical Center is a medical facility located in Hackensack, New Jersey. This center is recognized for care of Cancer, Lymphoma, Leukemia, Multiple Myeloma, Solid Tumors and other specialties. Hackensack University Medical Center is involved with conducting 982 clinical trials across 1,009 conditions. There are 52 research doctors associated with this hospital, such as Martin E Gutierrez, Katharine Offer, Burton E. Appel, and Derek Hanson, MD.
Where is Hackensack University Medical Center located?
To reach Hackensack University Medical Center, located at 30 Prospect Avenue, Hackensack, New Jersey: Take I-80 West to NJ-17 South towards Paramus. Use the right two lanes to exit at 17A-17B for NJ-4 East towards Hackensack. Continue on NJ-4 East, then take the Prospect Avenue exit towards the hospital, which will be on your left.
Who should I call to ask about financial aid or insurance network?
For financial assistance, insurance, and billing inquiries at Hackensack University Medical Center, please call 888-568-3522. To request a copy of the Financial Assistance Policy and Application by mail, contact the Patient Financial Services department at (201) 383-1043. This policy covers all emergency and medically necessary services, including employed physician services and behavioral health.
What insurance does Hackensack University Medical Center accept?
Hackensack University Medical Center accepts a wide range of insurance plans, including but not limited to Aetna, Amerigroup, AmeriHealth, Cigna, Clover, Horizon BCBS, and United HC. The hospital is also part of various networks such as Aetna HMO/PPO, Amerihealth PPO/HMO, Cigna HMO/PPO, Horizon HMO/POS/EPO, and United Healthcare Choice Plus/PPO. Patients are advised to verify their eligibility and coverage directly with their insurance provider, as insurance agreements may change.
What awards or recognition has Hackensack University Medical Center received?
Hackensack University Medical Center, located in Hackensack, New Jersey, has been awarded nearly $1 million in grants by the New Jersey Health Foundation to support research in areas such as cancer, infectious disease, community health, education, diabetes, and rheumatology. It stands out as the only hospital in New Jersey to have both its adult and children's hospitals ranked #1, according to U.S. News & World Report, 2023-24. Furthermore, it is nationally-ranked in six specialties.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.